News Worldwide recognition!
AstroMelanin is a biotechnology product based on the production of a substance from Antarctic microorganisms. Studies of the substance were carried out by the biggest scientists in the field of oncology in Russia, USA, South Korea and Japan. Inventions are confirmed by patents and awarded with prizes at the International Salons of Inventions "Concourlepin", Paris, and "Eureka", Brussels (gold medal).
AstroMelanin received approving reviews and support from the heads of three oncological centers in Russia, which evaluated it as a promising drug that reflects the latest methods in the treatment of tumor diseases.
The work was carried out by a team of renowned Russian scientists-oncologists under the leadership of the Director of the Russian Oncological Center named after N.N.Blokhin RAMS Academician N.N.Trapeznikov and Director of the Research Institute for Experimental Diagnostics and Therapy of Tumors, Russian Cancer Research Center named after N.N.Blokhin RAMS, Doctor of Medical Sciences, Professor, Academician of the RMTA A.Y.Baryshnikov.
Research conducted by a world-renowned scientist, Dr. Van Hoff, Head of the Institute for Drug Development and Cancer Therapy in San Antonio, Texas, USA, showed that when exposed to a tumor for six days, "AstroMelanin COMPLETELY inhibits the growth of human breast cancer cells"
United Financial Group, together with a group of biologists and chemists, has been working on this development for 10 months with the aim of bringing it to the market. At the current stage, research work on the drug, analysis of the active substance, as well as preparation of preclinical studies of the drug AstroMelanin are underway.
For statistics, Humira by AbbVie Inс. is again the top-selling cancer treatment drug in the world. In 2020, Humira brought in revenues of $ 19.83 billion, up 3.5% from a year earlier.
Merck & Co. Inc. with the drug Keytruda received revenue of $ 14.38 billion, which is 29.7% more than in 2019; it is followed by Revlimid of Bristol-Myers Squibb Co. with sales of $ 12.11 billion.
Bristol Myers' Opdivo was one of just few cancer drugs, with revenues falling 2.9% in 2020 to $ 6.99 billion.